Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 18Recruiting 11Withdrawn 2Active not recruiting 2Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Neuroblastoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Eflornithine × Clear all
NCT01349881 2026-04-02

PACES

SWOG Cancer Research Network

Phase 3 Active not recruiting
354 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03794349 2026-02-18

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Children's Oncology Group

Phase 2 Active not recruiting
94 enrolled 14 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡